POZEN Inc. : PA32540 Provides Faster Gastric Acid Reduction Than Enteric-Coated Omeprazole (40 mg) – 4-traders (press release)

POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, presented data today from a Phase 1 study that found that the investigational compound, PA32540, provides faster protection compared with delayed …

Leave a Reply

Your email address will not be published. Required fields are marked *